Rapid Therapeutic Science Laboratories, Inc. (RTSL)
OTCMKTS: RTSL · Delayed Price · USD
0.0020
+0.0008 (66.67%)
Jul 26, 2024, 4:00 PM EDT - Market closed
RTSL Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
4
Market Cap
17.67K
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 379.49B |
| Johnson & Johnson | 78.71B |
| Merck & Co. | 61.40B |
| AbbVie | 54.40B |
| AstraZeneca | 49.13B |
| Novartis AG | 48.86B |
| Thermo Fisher | 42.49B |
| Abbott Laboratories | 40.33B |
RTSL News
- 1 year ago - White House Office of Management and Budget review on Cannabis-Derived Products confirms Rapid Therapeutic Science Laboratories' Long-Term Strategy - GlobeNewsWire
- 1 year ago - Rapid Therapeutic Science Laboratories Updates Patents - GlobeNewsWire
- 2 years ago - Rapid Therapeutic Science Laboratories File S1 and completes Mid-Year Strategy Review - GlobeNewsWire
- 2 years ago - Rapid Therapeutic Science Laboratories to Present at the Q4 Investor Summit Conference - GlobeNewsWire
- 2 years ago - Rapid Therapeutic Science Laboratories Secures Upgraded Laboratory and Manufacturing Facility - GlobeNewsWire